Phase III Randomized Study Of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC)- CALGB 80802 (Alliance) Abou-Alfa, Ghassan K. , Niedzwieski, Donna , Knox, Jennifer J. ... - ASCO GI - J. Clin. Oncol. - 2016 Abstract - Primary - Primary - GI - CALGB-80802
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma Abou-Alfa, Ghassan K. , Shi, Qian , Knox, Jennifer J. ... - - JAMA Oncol - 2019 Manuscript - Primary - Primary - GI - CALGB-80802
Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB 80802 (Alliance) (C8) Abou-Alfa, Ghassan K. , Shi, Qian , Knox, Jennifer J. ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80802
A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study. Adjei, A. A. , Mandrekar, S. J. , Dy, G. K. , Molina, J. R. ... - - J. Clin. Oncol. - 2008 Abstract - Primary - Primary - Respiratory - NCCTG-N0426
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426 Adjei, A. A. , Mandrekar, S. J. , Dy, G. K. , Molina, J. R. ... - - J. Clin. Oncol. - 2010 Manuscript - Primary - Primary - Respiratory - N0426
A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer. Adjei, A. A. , Molina, J. R. , Hillman, S. L. , Luyun, R. F. ... - - J. Clin. Oncol. - 2007 Abstract - Primary - Primary - Respiratory - NCCTG-N0326
Correlation between polymorphisms in the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer (NSCLC): An NCCTG N0026 based study. Abstract 198. Adjei, A. , Salavaggione, O. , Mandrekar, S. , Dy, G. ... - NCI TSM - - 2009 Abstract - Secondary-not-in-original - Primary - Respiratory - NCCTG-N0026
Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study. Adjei, Araba A , Salavaggione, Oreste E , Mandrekar, Sumithra J ... - - J Thorac Oncol - 2010 Manuscript - Secondary-not-in-original - Primary - Respiratory - N0026
Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance) Advani, Anjali S. , Sanford, Ben , Luger, Selina , Devidas, Meenakshi ... - ASH - Blood - 2013 Abstract - Secondary - Primary - Leukemia - C10403
Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial Advani, Pooja P. , Ballman, Karla V. , Dockter, Travis J. ... - - J. Clin. Oncol - 2016 Manuscript - Primary - Long-Term-Followup - Breast - N9831
Long-term cardiac safety analysis of NCCTG (Alliance) N9831 adjuvant trastuzumab (H) trial. Advani, Pooja Prem , Ballman, Karla V. , Dockter, Travis J. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary - Long-Term-Followup - Breast - N9831
A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: an Alliance Foundation trial (AFT-19) Aggarwal, Rahul , Eggener, Scott , Chen, Ronald , Heller, Glenn ... - ASCO - J Clin Oncol - 2018 Abstract - No-Endpoint - Trial-Description-Only - GU - AFT-19
The Effect of Prior Androgen Synthesis Inhibition on Outcomes of Subsequent Therapy with Docetaxel in Patients with Metastatic Castrate Resistant Prostate Cancer: Results from a Retrospective Analysis of a Randomized Phase 3 Clinical Trial (CALGB 90401) (Alliance) Aggarwal, Rahul , Halabi, Susan , Kelly, William Kevin ... - - Cancer - 2013 Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90401
Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM) CALGB 100104 (Alliance) Ailawadhi, Sikander , McCarthy, Philip L. , Holstein, Sarah A. ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Meta-Analysis - Transplant - CALGB-100104 , E4A03 , MM-002 , MM-009
Management of Recurrent Prostate Cancer after Radiotherapy: Long-term results from CALGB 9687, a Contemporary Prospective Multi-institutional Salvage Prostatectomy Series Al-Daghmin, A , Sokoloff, MH , Halabi, S , Sanford, BL , Eastham, JA ... - AUA - J Urology - 2014 Abstract - Primary - Long-Term-Followup - GU - CALGB-9687
Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia Alachkar, Houda , Fulton, Noreen , Sanford, Ben , Malnassy, Greg ... - - Pharmacogenomics J. - 2017 Manuscript - Secondary - Primary - Leuk Corr Sci - CALGB-10102
SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome Alachkar, Houda , Santhanam, Ramasamy , Maharry, Kati ... - - J. Clin. Invest - 2014 Manuscript - Secondary - Primary - Leuk Corr Sci - CALGB-19808 , CALGB-9621
Efficacy and toxicity of cetuximab (C225) plus mFOLOFX6 in patients (pts) with nonoptimally resectable, colorectal metastases (MCRC) confined to the liver Alberts, S. R. , Donohue, J. H. , Mahoney, M. R. , Nelson, G. D. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Primary - Primary - GI - NCCTG-N014A
NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)--interim review of toxicity Alberts, S. R. , Morlan, B. W. , Kim, G. P. , Pitot, H. C. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007 Abstract - Primary - Preliminary - GI - NCCTG-N044J
Adjuvant mFOLFOX6 +/- Cetuxiumab in KRAS Wild Type Patients With Resected Stage III Colon Cancer: NCCTG Intergroup Phase III Trial N0147. Alberts, S. R. , Sargent, D. J. , Smyrk, T. C. , Shields, A. F. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Primary - GI - NCCTG-N0147
Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147. Alberts, S. R. , Thibodeau, S. N. , Sargent, D. J. , Mahoney, M. R. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary - Primary - Correl Sci NOS - NCCTG-N0147
Systemic capecitabine and oxaliplatin administered with hepatic arterial infusion (HAI) of floxuridine (FUDR) following complete resection of colorectal metastases (M-CRC) confined to the liver. Alberts, S. , Mahoney, M. R. , Donohue, J. H. , Roh, M. S. ... - - J. Clin. Oncol. - 2007 Abstract - Primary - Primary - GI - NCCTG-N9945
Randomized phase II trial of extended versus standard neoadjuvant therapy for esophageal cancer, NCCTG (Alliance) trial N0849 Alberts, S. , Soori, G. , Shi, Q. , Wigle, D. , Sticca, R. , Miller, R. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary - Preliminary - GI - N0849
Cediranib (AZD2171) in Patients with Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial Alberts, Steven R. , Fitch, Tom R. , Kim, George P. ... - - Am. J. Clin. Oncol. - 2012 Manuscript - Primary - Primary - GI - N044J
Gemcitabine and Doxetaxel for Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial Alberts, Steven R. , Reid, Joel M. , Morlan, Bruce W. , Farr, Gist H. ... - - Am. J. Clin. Oncol. - 2012 Manuscript - Primary - Primary - GI - N0041
Alternating Systemic and Hepatic Artery Infusion Therapy for Resected Liver Metastases From Colorectal Cancer: A North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) Phase II Intergroup Trial, N9945/CI-66 Alberts, Steven R. , Roh, Mark S. , Mahoney, Michelle R. ... - - J Clin Oncol - 2010 Manuscript - Primary - Primary - GI - N9945
Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer Alberts, Steven R. , Sargent, Daniel J. , Nair, Suresh ... - - JAMA - 2012 Manuscript - Primary - Primary - GI - N0147
Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943. Alberts, Steven R , Sande, Jonathan R , Foster, Nathan R ... - - J Gastrointest Cancer - 2007 Manuscript - Primary - Primary - GI - NCCTG-N9943
Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial. Alberts, Steven R , Suman, Vera J , Pitot, Henry C ... - - J Gastrointest Cancer - 2007 Manuscript - Primary - Primary - GI - NCCTG-964251
Computed tomography densitometry and morphology of radiofrequency ablated Stage IA non-small cell lung cancer: Results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial Alexander, Erica S. , Xiong, Lillian , Baird, Grayson L. ... - - J Vasc Interv Radiol - 2020 Manuscript - Secondary-not-in-original - Primary - Respiratory - ACOSOG-Z4033
ACOSOG Z0030 Study Group: Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective ACOSOG Z0030 trial Allen, M. S. , Darling, G. E. , Decker, P. A. , Putnam, J. B. Jr ... - - J. Clin. Oncol. - 2007 Abstract - Secondary-not-in-original - Primary - Respiratory - ACOSOG-Z0030
Perioperative mortality and Morbidity after Lobar versus Sublobar Resection for early stage lung cancer: A post-hoc analysis of an international randomized phase III trial (CALGB/Alliance 140503) Altorki, Nasser K. , Wang, Xiaofei , Wigle, Dennis , Gu, Lin ... - - Lancet Respir Med - 2018 Manuscript - Secondary-not-in-original - Primary - Respiratory - ACOSOG-Z0010
Perioperative mortality and Morbidity after Lobar versus Sublobar Resection for early stage lung cancer: A post-hoc analysis of an international randomized phase III trial (CALGB/Alliance 140503) Altorki, Nasser K. , Wang, Xiaofei , Wigle, Dennis , Gu, Lin ... - AATS - - 2018 Abstract - Secondary-not-in-original - Primary - Respiratory - CALGB-140503
Par-4 Down-regulation Promotes Breast Cancer Recurrence by Preventing Multinucleation following Targeted Therapy Alvarez, James V. , Pan, Tien-chi , Ruth, Jason , Feng, Yi ... - - Cancer Cell - 2013 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-150007
Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods An, Ming-Wen , Han, Yu , Meyers, Jeffrey P. , Bogaerts, Jan ... - - J. Clin. Oncol - 2015 Manuscript - Secondary-not-in-original - Primary - GI - NCCTG-N9741
Exploring the statistical and clinical impact of two interim analyses on the phase II design with option for direct assignment An, Ming-Wen , Mandrekar, Sumithra J. , Edelman, Martin J. ... - - Contemp Clin Trials - 2014 Manuscript - Secondary-not-in-original - Primary - Respiratory - CALGB-30203
Single nucleotide polymorphisms (SNPs) and circulating endothelial cells (CECs) as outcome predictors in recurrent glioblastoma (rGBM) patients (pts) treated with bevacizumab (BEV) and sorafenib (SOR). Anderson, S. K. , Lafky, J. M. , Carrero, X. W. , Kimlinger, T. K. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original - Primary - Neuro-Onc - NCCTG-N0776
Validating RNAseq-Signatures of Vorinostat (VOR) Sensitivity and Resistance in Patients with Newly Diagnosed Glioblastoma (GBM) Treated with VOR, Temozolomide and Radiation Therapy From Alliance N0874/ABTC-0902. Anderson, S. Keith , Miller, C. Ryan , Sarkaria, Jann N. ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary - Primary - Neuro-Onc - N0874 , ABTC-0902
Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978-1995 versus 1996-2007: Impact on recurrence rate, time from recurrence to death (TRD), and overall survival (OS) -- Findings from the ACCENT dataset. Andre, T. , Shi, Q. , Yothers, G. , Bot, B. , Haller, D. ... - ASCO - J. Clin. Oncol. - 2010 Abstract - Secondary - Primary - GI - NCCTG-N0441
Phase II clinical trial of denileukin diftitox in combination with rituximab in previously untreated follicular B-cell non-Hodgkins lymphoma Ansell, S. M. , Tang, H. , Nowakowski, G. S. , Nikcevich, D. A. ... - ASH - 53rd ASH Annual Meeting and Exposition - 2010 Abstract - Primary - Primary - Lymphoma - NCCTG-N0682
Low-Dose, Single-Agent Temsirolimus for Relapsed Mantle Cell Lymphoma Ansell, Stephen M. , Inwards, David J. , Rowland, Kendrith M. ... - - Cancer - 2008 Manuscript - Primary - Primary - Lymphoma - N0186
Serum BLyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma Ansell, Stephen M. , Novak, Anne J. , Ziesmer, Steven ... - - Am J Hematol - 2009 Manuscript - Secondary - Primary - Lymphoma - NCCTG-98-78-51
Temsirolimus and Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma: a multi-center Phase 2 Study Ansell, Stephen M. , Tang, Hui , Kurtin, Paul J. ... - - Lancet Oncol - 2011 Manuscript - Primary - Primary - Lymphoma - N038H
Denileukin Diftitox in Combination with Rituximab for Previously Untreated Follicular B-cell Non-Hodgkin’s Lymphoma Ansell, Stephen M. , Tang, Hui , Kurtin, Paul J. ... - - Leukemia - 2012 Manuscript - Primary - Primary - Lymphoma - NCCTG-N0682
Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance). Anurag, Meenakshi , Zhu, Mayanne , Huang, Chen , Vasaikar, Suhas ... - - J. Natl. Cancer Inst. - 2019 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - ACOSOG-Z1031
Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy Apolo, Andrea B. , Ostrovnaya, Irina , Halabi, Susan ... - - J. Natl. Cancer Inst - 2013 Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90102
External validation of prognostic models for overall survival (OS) in patients (pts) with advanced cancer (UC) treated with cisplatin-based chemotherapy. Apolo, Andrea Borghese , Philips, George , Ostrovnaya, Irina ... - - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original - Primary - GU - CALGB-90102
Alliance A031501: Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (MIBC) (AMBASSADOR) vs Observation Apolo, Andrea , Rosenberg, Jonathan , Morris, Michael ... - ASCO GU - J Clin Oncol - 2019 Abstract - No-Endpoint - Trial-Description-Only - GU - A031501
Surgical practice patterns following NCCTG N0338 Phase II trial of docetaxel and darboplatin administered every two weeks as induction therapy for stage II and stage III breast cancer. Apsey, H. , Roy, V. , Pockaj, B. , Northfelt, D. , Sticca, R. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary - Primary - Breast - NCCTG-N0338
Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: Results of ACOSOG (American College Of Surgeons Oncology Group) Z1071 (Alliance) Substudy Armer, Jane M. , Ballman, Karla V. , McCall, Linda , Armer, Nathan C. ... - - Support Care Cancer - 2019 Manuscript - Secondary - Primary - Breast - ACOSOG-Z1071
Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection Armer, Jane M. , Ballman, Karla V. , McCall, Linda , Ostby, Pamela L. ... - - JAMA Surg - 2019 Manuscript - Secondary - Primary - Breast - ACOSOG-Z1071
Lymphedema results of Alliance Z1071 (American College of Surgeons Oncology Group [ACOSOG]): Self-reported symptoms and limb volume changes for breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection Armer, Jane M. , Ballman, Karla , McCall, Linda , Suman, Vera ... - ILF - - 2018 Abstract - Secondary - Primary - Breast - ACOSOG-Z1071
Symptoms and limb changes for breast cancer survivors treated with neoadjuvant chemotherapy: Lymphedema results of ACOSOG Z1071 (Alliance) Armer, Jane M. , Ballman, Karla , McCall, Linda , Suman, Vera ... - MASCC / ISOO - Supportive Cancer Care - 2017 Abstract - Secondary - Primary - Breast - ACOSOG-Z1071
Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Ashley, Amanda C , Sargent, Daniel J , Alberts, Steven R ... - - Cancer - 2007 Manuscript - Primary - Long-Term-Followup - GI - NCCTG-9741
Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS) CALGB 100104 (Alliance) Attal, Michel , Palumbo, Antonio , Holstein, Sarah ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104
Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60–75 Years: Cancer and Leukemia Group B (CALGB) Study 10502 Attar, E. C. , Donohue, K. A. , Amrein, P. C. , Wadleigh, M. ... - - Blood - 2010 Abstract - Primary - Preliminary - Leukemia - CALGB-10502
A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502. Attar, E. C. , Johnson, J. L. , Amrein, P. C. , Lozanski, G. ... - - J. Clin. Oncol. - 2012 Abstract - Primary - Primary - Leukemia - CALGB-10502
Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study Attar, E. C. , Maharry, K. , Mrozek, K. , Radmacher, M. D. ... - ASH - Blood - 2009 Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-10502 , CALGB-20202 , CALGB-20502 , CALGB-8461
Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502 Attar, Eyal C. , Johnson, Jeffrey L. , Amrein, Philip C. ... - - J. Clin. Oncol. - 2013 Manuscript - Primary - Primary - Leukemia - CALGB-10502
Cytarabine, daunorubicin and etoposide (ADE) chemotherapy in acute myeloid leukemia (AML) patients >= 60 years (CALGB 9720) Baer, M. R. , George, S. L. , Sanford, B. L. , Bothun, S. M. ... - - Blood - 2007 Abstract - Secondary - Primary - Leukemia - CALGB-8461 , CALGB-9720
Treatment of older patients with de novo acute myeloid leukemia (AML) with one or more postremission chemotherapy courses: Analysis of four CALGB studies Baer, M. R. , George, S. L. , Sanford, B. L. , Stone, R. M. ... - ASCO - J. Clin. Oncol. - 2010 Abstract - Secondary-not-in-original - Comprehensive - Leukemia - C8525 , CALGB-10201 , CALGB-8923 , CALGB-9720
Cancer and Leukemia Group B studies of recombinant Interleukin-2 maintenance therapy in acute myeloid leukemia Baer, M. R. , Kolitz, J. E. , George, S. L. , Caligiuri, M. A. ... - - Ann Hematol - 2008 Abstract - No-Endpoint - Comprehensive - Leukemia - CALGB-19808
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720 Baer, MR , George, SL , Sanford, BL , Mrózek, K , Kolitz, JE ... - - Leukemia - 2011 Manuscript - Primary - Primary - Leukemia - CALGB-9720
Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720 Baer, Maria R. , George, Stephen L. , Caligiuri, Michael A. ... - - J Clin Oncol - 2008 Manuscript - Secondary - Primary - Leukemia - CALGB-8461 , CALGB-9720
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720 Baer, Maria R. , George, Stephen L. , Caligiuri, Michael A. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary - Primary - Leukemia - CALGB-10201 , CALGB-10502 , CALGB-10503 , CALGB-10603 , CALGB-19808 , CALGB-8525 , CALGB-8923 , CALGB-9022 , CALGB-9222 , CALGB-9420 , CALGB-9621 , CALGB-9720
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study—CALGB 30607 (Alliance) Baggstrom, Maria Q. , Socinski, Mark A. , Wang, Xiaofei F. , Gu, Lin ... - - J Thorac Oncol - 2017 Manuscript - Primary - Primary - Respiratory - CALGB-30607 , CALGB-70701
Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903). Bajorin, Dean F , Halabi, Susan ... - - Clin Genitourin Cancer - 2009 Manuscript - Primary - Primary - GU - CALGB-99903
A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101 Baldwin, R. Michael , Owzar, Kouros , Zembutsu, Hitoshi ... - - Clin. Cancer Res. - 2012 Manuscript - Secondary-not-in-original - Primary - PPP - CALGB-40101
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme Ballman, Karla V. , Buckner, Jan C. , Brown, Paul D. ... - - Neuro-oncol - 2007 Manuscript - Primary - Primary - Neuro-Onc - N047D
Adjuvant chemotherapy for resected stage II and III colon cancer: Comparison of widely used two prognostic calculators Bardia, A. , Loprinzi, C. , Grothey, A. , Nelson, G. , Alberts, S. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary-not-in-original - Primary - GI - NCCTG-N0148
Adjuvant Chemotherapy for Resected Stage II and III Colon Cancer: Comparison of Two Widely Used Prognostic Calculators Bardia, Aditya , Loprinzi, Charles , Grothey, Axel , Nelson, Garth ... - - Semin Oncol - 2010 Manuscript - Secondary-not-in-original - Primary - GI - N0148
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Bartlett, N L , Niedzwiecki, D , Johnson, J L , Friedberg, J W ... - - Ann. Oncol. - 2007 Manuscript - Primary - Primary - Lymphoma - CALGB-59804
A phase I/II study of gemcitabine, vinorelbine, and liposomal doxorubicin for relapsed Hodgkin's disease: Preliminary results of CALGB 59804 Bartlett, N. , Niedzwiecki, D. , Johnson, J. , Friedberg, J. W. ... - - Proc Am Soc Clin Oncol - 2003 Abstract - Primary - Primary - Lymphoma - CALGB-59804
Phase II Study of 9-aminocamptothecin in Previously Treated Lymphomas: Results of Cancer and Leukemia Group B 9551 Bartlett, Nancy L. , Johnson, Jeffrey L. , Wagner-Johnston, Nina ... - - Cancer Chemother. Pharmacol. - 2009 Manuscript - Primary - Primary - Lymphoma - CALGB-9551
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303 Bartlett, Nancy L. , Wilson, Wyndham H. , Jung, Sin-Ho , Hsi, Eric D. ... - - J. Clin. Oncol - 2019 Manuscript - Primary - Primary - Lymphoma - CALGB-50303
Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Patients with Hematologic Malignancies Who Relapse following Autologous Transplantation: A Multi-Institutional Prospective Study from the Cancer and Leukemia Group B (CALGB trial 100002) Bashey, Asad , Owzar, Kouros , Johnson, Jeffrey L. ... - - Biol. Blood Marrow Transplant. - 2011 Manuscript - Primary - Primary - Transplant - CALGB-100002
Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in CALGB 51101 (Alliance) Batchelor, T , Giri, S , Stark, A , Bartlett, N , Hsi, E , Cheson, B ... - ASCO - J Clin Oncol. - 2020 Abstract - Primary - Primary - Lymphoma - CALGB-51101
Her2 gene expression and not Her2 amplification is predictive and prognostic in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405 (Alliance) Battaglin, Francesca , Ou, Fang-Shu , Qu, Xueping ... - ASCO - J. Clin. Oncol - 2020 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-80405
Sole Trisomy 8 In Patients (pts) with De Novo Acute Myeloid Leukemia (AML) Is Associated with Age-Independent Poor Outcome That Is Modified by Molecular Markers and with Unique Gene- and Microrna (miR)-Signatures: a Cancer and Leukemia Group B (CALGB) Study Becker, H. , Maharry, K. , Radmacher, M. D. , Margeson, D. ... - - Blood - 2010 Abstract - Secondary - Primary - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720
NPM1 mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML) Becker, H. , Marcucci, G. , Maharry, K. , Margeson, D. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-10201 , CALGB-20202 , CALGB-8461 , CALGB-9720
Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (>= 60 years y ) and Younger (< 60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study Becker, H. , Marcucci, G. , Maharry, K. , Radmacher, M. D. ... - - Blood - 2009 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720
CEBPA double mutations impact favorably on the outcome of older adults with wild-type NPM1 cytogenetically normal acute myeloid leukemia and are associated with distinct gene- and microRNA-expression patterns Becker, H. , Marcucci, G. , Maharry, K. , Radmacher, M. , Wu, Y. ... - - Haematologica - 2010 Abstract - Secondary - Primary - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9665 , CALGB-9720
Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8 Becker, Heiko , Maharry, Kati , Mrózek, Krzysztof , Volinia, Stefano ... - - Leukemia - 2014 Manuscript - Secondary - Primary - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-10502 , CALGB-10503 , CALGB-10603 , CALGB-19808 , CALGB-8923 , CALGB-9022 , CALGB-9222 , CALGB-9420 , CALGB-9621 , CALGB-9720
Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study Becker, Heiko , Maharry, Kati , Radmacher, Michael D. ... - - Haematologica - 2011 Manuscript - Secondary - Primary - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720
Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study Becker, Heiko , Marcucci, Guido , Maharry, Kati ... - - Blood - 2010 Manuscript - Secondary - Primary - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720
Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study Becker, Heiko , Marcucci, Guido , Maharry, Kati ... - - J Clin Oncol - 2010 Manuscript - Secondary - Primary - Leuk Corr Sci - CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-8461 , CALGB-9720
Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy Beltran, Himisha , Wyatt, Alexander W , Chedgy, Edmund C ... - - Clin. Cancer Res. - 2017 Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90203
New strategies to improve drug development in carcinoid tumors (Alliance A021202) Bergsland, Emily K. , Mahoney, Michelle R. , Asmis, Timothy R. ... - NETRF - - 2019 Abstract - No-Endpoint - Trial-Description-Only - GI - A021202
Randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202). Bergsland, Emily K. , Mahoney, Michelle R. , Asmis, Timothy R. ... - ASCO - J Clin Oncol - 2019 Abstract - Primary - Primary - GI - A021202
Randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202). Bergsland, Emily K. , Mahoney, Michelle R. , Asmis, Timothy R. ... - NANETS - Pancreas - 2019 Abstract - Primary - Primary - GI - A021202
Adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression: patient-reported outcomes in the TEXT and SOFT randomised trials Bernhard, Jürg , Luo, Weixiu , Ribi, Karin , Colleoni, Marco ... - - Lancet Oncol. - 2015 Manuscript - Secondary - Primary - Breast - IBCSG-24-02 (SOFT-TEXT)
High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 15 randomized adjuvant breast cancer trials Berry, D. A. , Ueno, N. T. , Johnson, M. M. , Lei, X. , Lopez, V. ... - - Breast Cancer Res. Treat. - 2007 Abstract - Primary - Primary - Breast - INT-0163
High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials Berry, Donald A. , Ueno, Naoto T. , Johnson, Marcella M. ... - - J. Clin. Oncol - 2011 Manuscript - Secondary-not-in-original - Comprehensive - Breast - INT-0163
Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581 Bertagnolli, M. M. , Niedzwiecki, D. , Hall, M. , Jewell, S. D. ... - ASCO - J. Clin. Oncol. - 2009 Abstract - Secondary - Primary - GI - C9581
Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803 Bertagnolli, Monica M. , Niedzwiecki, Donna , Compton, Carolyn C. ... - - J Clin Oncol - 2009 Manuscript - Secondary - Primary - GI - CALGB-150705 , CALGB-89803
Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer—A Study of CALGB 9581 and 89803 Bertagnolli, Monica M. , Redston, Mark , Compton, Carolyn C. ... - - J Clin Oncol - 2011 Manuscript - Primary - Primary - GI - C150705 , C89803 , C9581
p27Kip1 in Stage III Colon Cancer: Implications for Outcome Following Adjuvant Chemotherapy in CALGB 89803 Bertagnolli, Monica M. , Warren, Robert S. , Niedzwiecki, Donna ... - - Clin Cancer Res - 2009 Manuscript - Secondary - Primary - GI - CALGB-150705 , C89803
Effect of age on the pharmacokinetics of busulfan (Bu): An Alliance study. Beumer, J. H. , Lewis, L. D. , Owzar, K. , Jiang, C. , Holleran, J. L. ... - - J. Clin. Oncol. - 2012 Abstract - Secondary - Primary - PPP - CALGB-10503 , CALGB-19808 , CALGB-100103
Effect of Age on the Pharmacokinetics of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation; an Alliance study (CALGB 10503, 19808, and 100103) Beumer, Jan H. , Owzar, Kouros , Lewis, Lionel D. , Jiang, Chen ... - - Cancer Chemother. Pharmacol. - 2014 Manuscript - Secondary - Primary - PPP - C19808 , CALGB-100103 , CALGB-10503
An intensive sequenced adjuvant chemotherapy regimen for breast cancer. Bhardwaj, S , Holland, J F ... - - Cancer Invest. - 1993 Manuscript - Primary - Primary - Breast - C8743
Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3) Bhatnagar, B , Blachly, JS , Kohlschmidt, J , Eisfeld, A-K ... - - Leukemia - 2016 Manuscript - Secondary - Primary - Leuk Corr Sci - C8461 , CALGB-20202 , C8525 , CALGB-10102 , CALGB-10201 , CALGB-10503 , CALGB-10603 , CALGB-11002 , CALGB-19808 , CALGB-8923 , CALGB-9120 , CALGB-9222 , CALGB-9621 , CALGB-9720
Acute myeloid leukemia (AML) patients with an isolated trisomy display increased frequency of spliceosome mutations CALGB 8461 and 20202 (Alliance) Bhatnagar, Bhavana , Eisfeld, Ann-Kathrin , Mrózek, Krzysztof ... - ASH - Blood - 2017 Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - CALGB-20202 , CALGB-8461
Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia Bhatnagar, Bhavana , Eisfeld, Ann-Kathrin , Nicolet, Deedra ... - - Br. J. Haematol. - 2016 Manuscript - Secondary - Primary - Leuk Corr Sci - CALGB-20202 , CALGB-10201 , CALGB-10502 , CALGB-10503 , CALGB-10603 , CALGB-19808 , CALGB-9222 , CALGB-9621 , CALGB-9720
Discovery of SNPs associated with chemotherapy-induced peripheral neuropathy (CIPN) using model estimated parameters as phenotypes CALGB 40502 (Alliance) Bhongsatiern, Jiraganya , Carbonetto, P. , Chua, Katherina C. ... - ASCPT - CLINICAL PHARMACOLOGY & THERAPEUTICS - 2018 Abstract - Secondary-not-in-original - Primary - PPP - CALGB-40502
Mutational Landscape and Clinical Outcome Associated with Different Rearrangements Involving 11q23/MLL in De Novo Acute Myeloid Leukemia (AML) CALB 8461 and 20202 (Alliance) Bill, Marius , Eisfeld, Ann-Kathrin , Mrózek, Krzysztof ... - ASH - Blood - 2017 Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - CALGB-20202 , CALGB-8461
Prognostic impact of the 2017 European Leukemianet (ELN) classification of adult patients (pts) with acute myeloid leukemia (AML) treated on Cancer and Leukemia Group B (CALGB)/Alliance protocols Bill, Marius , Mrózek, K , Kohlschmidt, J. , Nicolet, D. ... - EHA - HemaSphere - 2019 Abstract - Secondary-not-in-original - Meta-Analysis - Leuk Corr Sci - C8461 , CALGB-20202 , CALGB-9665
Personalized Oncology in Acute Myeloid Leukemia (AML): Validation of the Prognostic Value of the Knowledge Bank Approach in Patients (Pts) Treated on Cancer and Leukemia Group B/Alliance Protocols Bill, Marius , Mrózek, Krzysztof , Kohlschmidt, Jessica ... - ASH - Blood - 2019 Abstract - Secondary-not-in-original - Primary - Leukemia - CALGB-20202 , CALGB-8461 , CALGB-9665
A 17-gene leukemia stem cell (LSC) score in adult patients (pts) with acute myeloid leukemia (AML) reveals a distinct mutational landscape and refines current European Leukemianet (ELN) genetic risk stratification (Alliance) Bill, Marius , Nicolet, Deedra , Eisfeld, Ann-Kathrin ... - ASH - Blood - 2018 Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - CALGB-20202 , CALGB-8461
Mutations associated with a 17-gene leukemia stem cell score and the score’s prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia Bill, Marius , Nicolet, Deedra , Kohlschmidt, Jessica ... - - Haematologica - 2020 Manuscript - Secondary-not-in-original - Primary - Leuk Corr Sci - C8621 , CALGB-8461 , C8721 , CALGB-10201 , CALGB-10502 , CALGB-10503 , CALGB-10603 , CALGB-11001 , CALGB-11002 , CALGB-19808 , CALGB-20202 , CALGB-8525 , CALGB-8821 , CALGB-8923 , CALGB-9022 , CALGB-9120 , CALGB-9222 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720
Prognostic and biologic significance of transfer RNA-derived small RNAs(tsRNAs) expression in younger adult patients (pts) with cytogenetically normal acute myeloid leukemia (CN-AML) Bill, Marius , Veneziano, Dario , Kohlschmidt, Jessica ... - ASH - Blood - 2018 Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - C8461 , C9665 , CALGB-20202
Demonstrating the value of coincidence analysis for identifying successful implementation strategies Birken, Sarah A. , Hwang, Soohyun , Viera, Laura , Haines, Emily ... - SIRC - - 2019 Abstract - No-Endpoint - Primary - ACS CCDRC - A23_Pilot2
Validating results from coincidence analysis (a variant of qualitative comparative analysis) using multiple models from diverse stakeholders Birken, Sarah A. , Hwang, Soohyun , Whitaker, Rebecca , James, Ted A. ... - DIH - - 2019 Abstract - No-Endpoint - Primary - ACS CCDRC - A23_Pilot2
Induction (Ind) plus concurrent (Con) chemotherapy with high-dose (74 Gy) 3-dimensional (3-D) thoracic radiotherapy (TRT) in stage III non-small cell lung cancer (NSCLC): Preliminary report of Cancer and Leukemia Group B (CALGB) 30105 Blackstock, A. W. , Socinski, M. A. , Bogart, J. , Gu, L. , Wang, X. ... - - J. Clin. Oncol. - 2006 Abstract - Primary - Primary - Respiratory - CALGB-30105
Impact of young (Y) age on efficacy and safety in advanced colorectal cancer (aCRC): A pooled analysis examining 6,286 patients (pts) from nine first-line phase III chemotherapy (CT) trials Blanke, C. D. , Bot, B. M. , Thomas, D. M. , Bleyer, A. , Kohne, C. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary-not-in-original - Comprehensive - GI - NCCTG-N9741
Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials Blanke, Charles D. , Bot, Brian M. , Thomas, David M. ... - - J. Clin. Oncol - 2011 Manuscript - Secondary-not-in-original - Comprehensive - GI - N9741
Meta-analyses of 22 randomized trials assessing the influence of chemotherapy in advanced/recurrent gastric cancer. Bleiberg, H. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original - Comprehensive - GI - NCCTG-79-41-51 , NCCTG-83-41-51
Alliance A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) Vaccine Given with Bevacizumab versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Bloch, Orin , Shi, Qian , Anderson, S. Keith , Knopp, Michael ... - SNO - Neuro-Oncology - 2017 Abstract - Primary - Primary - Neuro-Onc - A071101
Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502 Blum, K. A. , Johnson, J. L. , Jung, S.-H. , Cheson, B. D. ... - - Blood - 2008 Abstract - Primary - Primary - Lymphoma - CALGB-50502
Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism Blum, K. A. , Jung, S.-H. , Johnson, J. L. , Lin, T. S. , Hsi, E. D. ... - - Ann Oncol - 2010 Manuscript - Primary - Primary - Lymphoma - CALGB-50502
Randomized phase 2 trial of ofatumumab and bendamustine versus ofatumumab, bendamustine and bortezomib induction and maintenance therapy in patients (pts) with previously untreated high risk follicular lymphoma (FL): results from CALGB 50904 (Alliance) Blum, Kristie A. , Jung, Sin-Ho , Barak, Ian , Hsi, Eric D. ... - ASH - Blood - 2017 Abstract - Primary - Primary - Lymphoma - CALGB-50904
Randomized Trial of Ofatumumab and Bendamustine versus Ofatumumab, Bendamustine and Bortezomib in previously untreated patients with highrisk follicular lymphoma: CALGB 50904 (Alliance) Blum, Kristie A. , Polley, Mei-Yin , Jung, Sin-Ho ... - - Cancer - 2019 Manuscript - Primary - Primary - Lymphoma - CALGB-50904
Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Blum, Kristie A , Johnson, Jeffrey L , Niedzwiecki, Donna ... - - Leuk. Lymphoma - 2007 Manuscript - Primary - Primary - Lymphoma - CALGB-50206
Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153. Blum, Kristie A , Johnson, Jeffrey L , Niedzwiecki, Donna ... - - Cancer - 2006 Manuscript - Primary - Long-Term-Followup - Lymphoma - CALGB-9153
Challenges for conducting clinical trials evaluating maintenance chemotherapy in acute myeloid leukemia (AML): a Cancer and Leukemia Group B (CALGB) study Blum, W. , Donohue, K. , Marcucci, G. , Deangelo, D. J. , Uy, G. L. ... - ASH - Blood - 2010 Abstract - No-Endpoint - Comprehensive - Leukemia - CALGB-10503
Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance) Blum, W. , Sanford, B. , Klisovic, R. B. , Deangelo, D. J. , Uy, G. ... - ASH - Blood - 2012 Abstract - Primary - Primary - Leukemia - CALGB-10503
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B study (CALGB 10503) Blum, William , Sanford, Ben L. , Klisovic, Rebecca ... - - Leukemia - 2017 Manuscript - Primary - Primary - Leukemia - CALGB-10503
Accelerated conformal radiotherapy for stage I non-small cell lung cancer (NSCLC) in patients with pulmonary dysfunction: A CALGB phase I study. Bogart, J. , Watson, D. , Seagren, S. , Blackstock, W. , Wang, X. ... - - J. Clin. Oncol. - 2007 Abstract - Primary - Primary - Respiratory - CALGB-39904
Phase I Study of Accelerated Conformal Radiotherapy for Stage I Non–Small-Cell Lung Cancer in Patients With Pulmonary Dysfunction: CALGB 39904 Bogart, Jeffrey A. , Hodgson, Lydia , Seagren, Stephen L. ... - - J Clin Oncol - 2010 Manuscript - Primary - Primary - Respiratory - CALGB-39904
Interruptions Of Once-Daily Thoracic Radiotherapy Do Not Correlate With Outcomes In Limited Stage Small Cell Lung Cancer: Analysis of CALGB Phase III Trial 9235 Bogart, Jeffrey A. , Watson, Dorothy , McClay, Edward F. ... - - Lung Cancer - 2008 Manuscript - Secondary - Primary - Respiratory - CALGB-9235
Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on the experimental thoracic radiotherapy (TRT) arms of CALGB 30610 (Alliance) / RTOG 0538 Bogart, Jeffrey , Wang, Xiaofei , Masters, Gregory , Zhu, Han ... - ESMO - Ann Oncol - 2019 Abstract - Secondary - Primary - Respiratory - CALGB-30610
Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52 Bolton, J. S. , O'Connell, M. J. , Mahoney, M. R. , Farr, G. H. Jr ... - - Clin Colorectal Cancer - 2012 Manuscript - Primary - Primary - GI - NCCTG-924652
Laparoscopically assisted vs open colectomy for colon cancer: a meta-analysis. Bonjer, H Jacob , Hop, Wim C J , Nelson, Heidi , Sargent, Daniel J ... - - Arch Surg - 2007 Manuscript - Secondary-not-in-original - Comprehensive - GI - NCCTG-1515
Phase IB study of sorafenib + evofosfamide in patients with advanced hepatocellular carcinoma (HCC) and renal cell carcinoma NCCTG N1153 (Alliance) Borad, Mitesh J. , Foster, Nathan R. , Martin, Peter R. ... - ESMO GI - Ann. Oncol. - 2016 Abstract - Primary - Preliminary - Experimental - N1153
Activating Mutations in PIK3CA or AKT1 in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657) Boudreau, A. , Yau, C. , Petrillo, L. , Stemke-Hale, K. , Mills, G. ... - SABCS - Cancer Res. - 2011 Abstract - Secondary - Primary - Correl Sci NOS - ACRIN-6657 , CALGB-150007
Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 Boughey, J. C. , Suman, V. J. , Mittendorf, E. A. , Ahrendt, G. M. ... - SSO - Annals of Surgical Oncology - 2013 Abstract - Secondary - Primary - Breast - ACOSOG-Z1071
The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy – results from the ACOSOG Z1071 trial Boughey, J. , Suman, V. , Mittendorf, E. , Ahrendt, G. , Wilke, L. ... - - Cancer Res. - 2012 Abstract - Primary - Primary - Breast - ACOSOG-Z1071
Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance) Boughey, Judy C. , Ballman, Karla V. , Hunt, Kelly K. ... - - J. Clin. Oncol - 2015 Manuscript - Secondary - Primary - Breast - ACOSOG-Z1071
Identification and resection of the clipped node decreases the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy – results from ACOSOG Z1071 (Alliance) Boughey, Judy C. , Ballman, Karla V. , Le-Petross, Huong T. ... - - Ann. Surg. - 2016 Manuscript - Secondary-not-in-original - Primary - Breast - ACOSOG-Z1071
Tumor Biology and Response to Chemotherapy Impact Breast Cancer-Specific Survival in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Long-term Follow-up from ACOSOG Z1071 (Alliance) Boughey, Judy C. , Ballman, Karla V. , McCall, Linda M. ... - - Ann. Surg. - 2017 Manuscript - Secondary - Primary - Breast - ACOSOG-Z1071
Methods impacting the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4,N1-2) who receive neoadjuvant chemotherapy–results from a prospective trial–ACOSOG Z1071 (Alliance) Boughey, Judy C. , Ballman, Karla V. , Symmans, William F. ... - SABCS - Cancer Res - 2015 Abstract - Secondary - Primary - Breast - ACOSOG-Z1071
Axillary Ultrasound after Neoadjuvant Chemotherapy in Patients Presenting with Node-Positive Breast Cancer (T0-T4, N1-2, M0) and its Impact on Sentinel Lymph Node Surgery in ACOSOG Z1071 (Alliance) Boughey, Judy C. , Ballman, Karla , Hunt, Kelly K. , McCall, Linda M. ... - SIS - Journal of the Senologic International Society - 2014 Abstract - Secondary - Primary - Breast - ACOSOG-Z1071
Tumor biology and response to chemotherapy impact breast cancer specific survival in node positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection: Results from ACOSOG Z1071 (Alliance) Boughey, Judy C. , Ballman, Karla , McCall, Linda , Byrd, David ... - ASA - - 2017 Abstract - Secondary - Long-Term-Followup - Breast - ACOSOG-Z1071
Factors associated with lymphedema in patients/women with node positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection on a prospective clinical trial (Alliance) ACOSOG Z1071 Boughey, Judy C. , Ballman, Karla , McCall, Linda , Kuerer, Henry ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary - Primary - Breast - ACOSOG-Z1071
Predictors of locoregional recurrence after neoadjuvant chemotherapy and surgery for node positive breast cancer: Results from ACOSOG Z1071 (Alliance) Boughey, Judy C. , Ballman, Karla , McCall, Linda ... - SABCS - Cancer Res. - 2017 Abstract - Secondary-not-in-original - Primary - Breast - ACOSOG-Z1071
Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial Boughey, Judy C. , McCall, Linda M. , Ballman, Karla V. ... - - Ann. Surg. - 2014 Manuscript - Secondary - Primary - Breast - ACOSOG-Z1071
Effect of the use of immediate reconstruction on the rates of bilateral mastectomy and adjuvant radiation therapy use in women with node-positive breast cancer treated with neoadjuvant chemotherapy on ACOSOG Z1071 (Alliance). Boughey, Judy C. , McCall, Linda , Haffty, Bruce , Buchholz, Tom ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary-not-in-original - Primary - Breast - ACOSOG-Z1071
Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance) Boughey, Judy C. , Suman, Vera J. , Mittendorf, Elizabeth A. ... - - Ann. Surg. - 2015 Manuscript - Secondary - Primary - Breast - ACOSOG-Z1071
Sentinel Lymph Node Surgery after Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The American College of Surgeons Oncology Group (ACOSOG) Z1071 Clinical Trial Boughey, Judy C. , Suman, Vera J. , Mittendorf, Elizabeth A. ... - - JAMA - 2013 Manuscript - Primary - Primary - Breast - ACOSOG-Z1071
Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with stage I/II non-small cell lung cancer; Results from CALGB 159902 Boylan, Alice M. , Wang, Xiaofei F , Ko, Richard , Watson, Patricia M ... - - J. Thorac. Cardiovasc. Surg. - 2013 Manuscript - Secondary - Primary - Respiratory - CALGB-159902
LACE-Bio: validation of prognostic role of tumour lymphocytic infiltration in resectable non small cell lung cancer Brambilla, E. , Domerg, C. , Lantuejoul, S. , Kratzke, R. ... - - J Thorac Oncol - 2012 Abstract - Secondary-not-in-original - Comprehensive - Respiratory - CALGB-9633
LACE-Bio: results of pooled analysis of prognostic and predictive values of histology and lymphocytic infiltration Brambilla, E. , Tsao, M. , Paris, E. , Lantuejoul, S. ... - - Ann. Oncol. - 2010 Abstract - Secondary-not-in-original - Comprehensive - Respiratory - CALGB-9633
Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer Brambilla, Elisabeth , Le Teuff, Gwénaël , Marguet, Sophie ... - - J. Clin. Oncol - 2016 Manuscript - Secondary - Primary - Respiratory - CALGB-9633
Development of Clinical Precision Medicine Approaches in Meningiomas: Alliance A071401. Brastianos, Priscilla , Shi, Qian , Santagata, Sandro ... - SNOM - - 2016 Abstract - No-Endpoint - Trial-Description-Only - Neuro-Onc - A071401
Long term outcomes from intergroup NCCTG 86-72-51 (Alliance): Final report of a phase III prospective randomized trial of high dose versus low dose radiation therapy in adults with supratentorial low-grade glioma. Breen, William G. , Anderson, S. Keith , Carrero, Xiomara W ... - SNO - Neuro-Oncology - 2019 Abstract - Primary - Long-Term-Followup - Neuro-Onc - NCCTG-85-72-51
Final report from Intergroup NCCTG 86-72-51 (Alliance): a phase III randomized clinical trial of high-dose versus low-dose radiation for adult low-grade glioma
